Table 2.

Efficacy of intravenous Ig in patients with CIDP (the secondary measures)

	Week 1–28 (n=49)			Week 29–52 (n=38)*
	Week 1	Week 4	Week 28	Week 28*	Week 52
INCAT score	4.1 (1.4)	3.1 (1.8)	2.8 (1.9)†	2.2 (1.2)	1.9 (1.3)
ISS score	7.4 (4.2)	6.4 (4.5)	4.9 (3.8)†	4.3 (3.4)	4.4 (3.5)
Grip strength (kPa)
Dominant hand	37.1 (25.0)	46.4 (23.9)	50.1 (27.2)†	54.2 (24.9)	57.1 (26.8)
Non-dominant hand	36.6 (22.5)	46.5 (23.1)	49.4 (26.1)†	53.1 (24.0)	55.8 (25.7)
Total MRC score	50.7±7.3	53.8±7.8	54.5±8.4	57.0±4.5	56.9±4.9
CMAP amplitude (mV) (most affected nerve)	1.1 (1.8)‡	1.5 (2.5)§	1.8 (2.1)¶	1.8 (2.1)¶	1.7 (2.2)**
Serum IgG (mg/dL)	1210 (357)	2058 (369)††	1936 (369)‡‡	1936 (369)‡‡	2012 (341)¶

Data are shown as mean (SD).

*Only responders at week 28 were included.

†p<0.01, compared with a baseline value.

‡n=46.

§n=45.

¶n=34.

**n=32.

††n=48.

‡‡n=38.

CMAP, compound muscle action potential; INCAT, Inflammatory Neuropathy Cause and Treatment; ISS, INCAT sensory sum; MRC, Medical Research Council.